Form 4 for KURA Kura Oncology, Inc.
Accepted 2023-01-31 00:00:00 ET · period of report 2023-01-27 · accession 0001209191-23-005744 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-01-31 | 2023-01-27 | KURA | DALE STEPHEN | Chief Medical Off | S - Sale | $13.88 | -9,225 | 32.5K | -22% | -$128.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-27 | S | D | 4,840 | $13.87 | 27,675 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $13.62 to $14.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. (F2) This transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2022. |
| 2 | Common | Common Stock | 2023-01-27 | S | D | 4,385 | $13.89 | 32,515 | D | — | — | (F1) Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22. |